polatuzumab fda approval in dlbcl (polarix) & swog s1826 nivo vs. bv in hodgkin's lymphoma
Published 1 year ago • 2.3K plays • Length 21:26Download video MP4
Download video MP3
Similar videos
-
0:43
summary of two important lymphoma studies - polarix andd swog s1826 #oncology #cancer #lymphoma
-
0:41
results of swog s1826 study, showing nivo-avd better than bv-avd in hodgkin's lymphoma patients
-
0:58
polatuzumab in diffuse large b-cell lymphoma
-
1:15
swog s1826: promising results with the combination of nivolumab-avd in hodgkin lymphoma
-
10:42
asco23 - lba4: swog s1826, nivolumab(n)-avd vs. brentuximab vedotin(bv)-avd in advanced stage (a...
-
1:26
promising results from the swog s1826 trial: nivo-avd versus bv-avd in patients with chl
-
6:45
nivolumab chemotherapy in previously untreated stage iii or iv hodgkin lymphoma
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
4:47
the polarix trial: initial therapy of diffuse large b-cell lymphoma
-
1:41
swog s1826: nivolumab avd vs brentuximab vedotin avd for advanced stage hodgkin lymphoma
-
43:40
polatuzumab vedotin in previouslyuntreated diffuse large b-cell lymphoma.
-
2:20
nivolumab-avd vs brentuximab vedotin-avd in pediatric patients with chl: swog s1826 trial
-
1:34
dr. garcia on fda approval of pembrolizumab in bladder cancer
-
1:14
checkmate 205 study results: nivolumab in classical hodgkin lymphoma
-
2:30
new lymphoma drug studies show promise
-
1:04
bispecific afm13 plus pembro for r/r hodgkin lymphoma
-
1:29
phase ii evaluates vemurafenib/obinutuzumab in hairy cell leukemia
-
2:31
long-term follow up of study of obinutuzumab, polatuzumab vedotin, and lenalidomide in r/r fl
-
4:10
stephen m. ansell, md, phd: nivolumab moves to hematology